Director/PDMR Shareholding

Spire Healthcare Group PLC

19 June 2025

 

Spire Healthcare Group plc (the "Company")

19 June 2025

Notification of Transactions of Persons Discharging Managerial Responsibilities

Grant of Long Term Incentive Plan (LTIP) awards

The Company announces that, on 19 June 2025, an additional performance share award was granted over the Company's ordinary shares of 1 pence each (the "Shares") in the form of nil cost options to the following Executive Director of the Company, under the rules of the Company's Long Term Incentive Plan, to reflect the recent change in his base salary that was disclosed in the 2024 Annual Report and Accounts.

Executive Director                Maximum number of Shares under award

Harbant Samra                       28,729

The number of Shares set out above, together with the 436,681 awards granted on 27 March 2025 (total number of 465,410 performance share awards in 2025) represent 200% of the Executive Director's current base salary.  It is the maximum number which may vest under the LTIP Awards following the end of the performance period (31 December 2027).  The shareholder-approved Remuneration Policy permits awards of up to 200% of base salary for Executive Directors.

The actual number of Shares which vest will depend on the extent to which the relevant performance conditions have been satisfied.

The performance conditions applicable to the LTIP Awards will be based as follows:

·    20% on relative total shareholder return (TSR) performance;

·    35% on ROCE performance;

·    15% on Hospital EBIT Margin performance; and

·    30% on two Operational Excellence measures.

Further details of these performance conditions were disclosed in the 2024 Annual Report and Accounts.

The share price used to determine the number of Shares under the LTIP awards was 174.04 pence, the same share price used for the initial LTIP award, being the average of the mid-market closing share price over the five trading days ending on 26 March 2025. This is the same share price that was used to determine the 2025 LTIP award for all participants.

Notes:

1)   For the Executive Director the 2025 LTIP awards described above will also be subject to a further two-year holding period following the vesting date.

2)   The actual number of shares which vest under the LTIP awards will depend on the extent to which the relevant performance conditions are satisfied in due course.

Name of contact and telephone number for queries:

Mantraraj Budhdev

Group General Counsel and Company Secretary

Spire Healthcare Group plc

Tel: [phone]

The information set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.

Notification and public disclosure of transaction by persons discharging managerial responsibility and persons closely associated with them

a)	Name	Harbant Samra
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Spire Healthcare Group plc
b)	LEI	213800IBJPW3SE2RA350
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each GB00BNLPYF73
b)	Nature of the transaction	Grant of performance share awards under the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	28,729
d)	Aggregated information - Aggregated volume - Price	As above
e)	Date of the transaction	2025-06-19
f)	Place of the transaction	Outside of trading venue

 

END